From selecting the appropriate trial sites with a representative patient population to ensuring fast turnarounds with local regulations, VaxTRIALS has been pioneering solutions designed to manage and monitor vaccine research across Latin America. The company focuses on optimizing the trial processes and its integration with robust and validated systems, automatically complying with industry standards. Alongside carrying out studies with a high volume of subjects, it provides external project support to clinical investigational sites in the development and decision-making processes of the trials.
“We participate from start to finish. This includes clinical trial design, protocol development, site identification, patient recruitment, clinical monitoring, clinical study reporting, and publication,” says Dr. Jose Jimeno, CEO of VaxTRIALS.
VaxTRIALS: Optimizing End-to-end Vaccine Trial Timeframes
The company has contributed to the recruitment of more than 38000 subjects and 300000 study visits in association with leading investigators across the region. VaxTRIALS has been actively involved in developing 6 vaccines licensed thanks to their contribution. Dr. Jose Jimeno and his team have led the regulatory pathway in developing novel oral polio vaccine type 2. These regulatory pathways also aided major vaccine manufacturers in developing the COVID vaccine. Bolstered by such diversified experiences, VaxTRAILS has been involved in more than 45 vaccine-related clinical, epidemiological, and health economics trials, from which 9 were COVID studies including more than 22.000 subjets.
Our team at VaxTRIALS has profound local regulatory knowledge in managing vaccine clinical trials with agility and flexibility to reduce the time to market in vaccine clinical trials
Latin America has contributed, through the participation of more than 100,000 patients, to the development of 80 of the 233 vaccines prequalified by the World Health Organization (WHO). There are 26 vaccine-preventable diseases in Latin America, of which 23 are covered by WHO prequalified vaccines. Latin America has participated in development of 21 of the 26 vaccines (the five exceptions are the vaccines for tick-borne encephalitis, hepatitis E, rabies, typhoid fever, and Japanese encephalitis).